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ease and osteoporosis, the combination of HCTZ 1 KHCO3Comparative effects of potassium chloride and bicarbonate on
may be preferable to that of HCTZ 1 KCl.thiazide-induced reduction in urinary calcium excretion.
Background. The chronic low-grade metabolic acidosis that
occurs in various renal disorders and in normal people, and
that is related both to dietary net acid load and age-related
Metabolic acidosis has been shown in in vitro and inrenal functional decline, may contribute to osteoporosis by
vivo studies both to dissolve bone directly and to increaseincreasing urine calcium excretion. Administration of potas-
sium (K) alkali salts neutralizes acid and lowers urine calcium osteoclast activity, which increases bone resorption, re-
excretion. Urine calcium excretion also can be reduced by the leasing skeletal calcium for renal excretion [1]. Metabolic
administration of thiazide diuretics, which are often given with acidosis also promotes bone resorption and renal calcium
supplemental K to avoid hypokalemia. We determined whether
excretion by directly inhibiting renal tubular calcium re-the K alkali salt potassium bicarbonate (KHCO3) and the thia-
absorption [2]. States of chronic metabolic acidosis, suchzide diuretic hydrochlorothiazide (HCTZ) combined is more
effective in reducing urinary calcium than KHCO3 alone or as those accompanying renal tubular acidosis and ure-
HCTZ combined with the conventionally coadministered non- mia, are associated with low bone mineral density. How-
alkalinizing K salt potassium chloride (KCl). ever, otherwise healthy people can also have a chronic
Methods. Thirty-one healthy men and women aged 50 or
low-grade metabolic acidosis, expressed as a rise in steady-greater were recruited for a four-week, double-blind, random-
state blood hydrogen ion levels and a fall in steady-stateized study. After a baseline period of 10 days with three 24-
hour urine and arterialized blood collections, subjects were plasma bicarbonate levels, which results from eating the
randomized to receive either HCTZ (50 mg) plus potassium typically high net acid-producing American diets and
(60 mmol daily) as either the chloride or bicarbonate salt. from the decline in renal function that accompanies in-Another 19 women received potassium bicarbonate (60 mmol)
creasing age [3, 4]. Neutralizing acidosis with potassiumalone. After two weeks, triplicate collections of 24-hour urines
bicarbonate reduces bone resorption, presumably in partand arterialized bloods were repeated.
Results. Urinary calcium excretion decreased significantly in by direct effects on bone and in part by promoting renal
all groups. KHCO3 alone and HCTZ 1 KCl induced similar retention of calcium [5].
decreases (20.70 6 0.60 vs. 20.80 6 1.0 mmol/day, respectively).
Urinary calcium excretion (UCaV) in humans can alsoCompared with those treatments, the combination of HCTZ 1
be reduced by the administration of thiazide diuretics,KHCO3 induced more than a twofold greater decrease in uri-
nary calcium excretion (21.8 6 1.2 mmol/day, P , 0.05). Both which have been found to improve bone mass [6–8] and
HCTZ 1 KHCO3 and KHCO3 alone reduced net acid excretion to reduce fracture risk in older subjects [9–12]. Combined
significantly (P , 0.05) to values of less than zero. treatment with an alkalinizing salt of potassium and thia-Conclusions. KHCO3 was superior to KCl as an adjunct to
zide might then be particularly useful in preserving boneHCTZ, inducing a twofold greater reduction in urine calcium
because of their additive effects in reducing urine calciumexcretion, and completely neutralizing endogenous acid pro-
duction so as to correct the pre-existing mild metabolic acidosis excretion and by the additional direct beneficial effect on
that an acid-producing diet usually induces in older people. bone of alkali administration. Coadministration of potas-
Accordingly, for reducing urine calcium excretion in stone dis-
sium with thiazides is appropriate, since thiazides usually
increase renal potassium excretion, although potassium
depletion is usually prevented or corrected by adminis-Key words: acid-base balance, metabolic acidosis, osteoporosis, hydro-
chlorothiazide, renal stones. tration of the nonalkalinizing salt potassium chloride.
To our knowledge, the effect of coadministration of
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sis. In such patients, no difference in urine calcium excre- under the same experimental conditions in which the
tion was found comparing thiazide alone with thiazide combination of potassium bicarbonate and thiazide was
plus potassium citrate [13, 14]. In rats treated with thia- tested, including subject characteristics, dose of potas-
zide, the addition of potassium bicarbonate did not re- sium bicarbonate, and study design. This permitted us
duce urine calcium excretion further and appeared to to determine whether the combined effect of thiazide
block the hypocalciuric response to thiazide [15]. and potassium bicarbonate was substantially different
Patients with hypercalciuria and calcium nephrolithia- from that of potassium bicarbonate alone. Since potas-
sis may not be the ideal population to test whether thia- sium chloride is without effect on calcium excretion
zides can augment the hypocalciuric effect of alkalinizing [16, 17], this design also permitted us to determine in
potassium salts, since they have a pre-existing disorder humans whether the urine calcium-lowering effects of
of calcium metabolism and potential damage to the kid- thiazide and potassium bicarbonate are additive. The
ney that might alter their renal responses to hypocalciuric latter question is important inasmuch as Goulding and
agents. Accordingly, in the present study, we examined McIntosh reported that in rats, potassium bicarbonate
the effect of combined thiazide and potassium bicarbon- blocks the hypocalciuric effect of HCTZ [15].
ate on urine calcium excretion in otherwise healthy older Healthy men and women over the age of 50 years were
subjects. We chose older men and women eating typical recruited. The women were at least five-years postmeno-
acid-producing diets, since such subjects are at higher pausal and not on estrogen replacement. Exclusion crite-
risk for osteoporosis and have low-grade metabolic aci- ria included the use of steroid hormones in the past two
dosis. In addition, we investigated whether the effect of years, the use of bisphosphonates in the past five years,
combined thiazide and potassium bicarbonate is more and any medical condition that increased bone turnover
effective in reducing urinary calcium than potassium bi- (immobilization, renal disease, metabolic disease, etc.).
carbonate alone or thiazide combined with the conven- Arterialized venous blood specimens were obtained
tionally coadministered nonalkalinizing K salt potassium without stasis, fist clenching, or exposure to air. Sponta-
chloride. neously voided urine specimens were maintained under
mineral oil and were preserved with thymol. Urine cal-
cium was determined by atomic absorption spectropho-METHODS
tometry. Plasma and urine total carbon dioxide contentWe compared the effect on renal calcium excretion of
was determined by either manometry (using the Natel-the combination of hydrochlorothiazide (HCTZ) and an
son microgasometer) or thermal conductivity (Corningalkalinizing salt of potassium, potassium bicarbonate,
CO2 analyzer); the two methods have similar precisionwith that of the combination of hydrochlorothiazide and
(Natelson, CV 5 1.2%; Ericson, CV 5 0.7%) and, withinthe nonalkalinizing salt potassium chloride. The study
an examined range of values of total carbon dioxidewas a double-blind, randomized study in free-living sub-
content from 22 to 33 mmol/L, yield nearly identicaljects, comparing the effect of oral administration of 60
values [Dx 5 0.1 6 0.5 (SD) mmol/L; N 5 27]. PlasmamEq (given as 20 mEq TID with meals) of either potas-
bicarbonate concentration and carbon dioxide tensionsium chloride (KCl) or potassium bicarbonate (KHCO3)
were calculated from the measured values of blood pHin combination with 50 mg/day (given as 25 mg BID) of
and plasma carbon dioxide content utilizing the Hender-HCTZ. The HCTZ 1 KCl group comprised 13 subjects
son-Hasselbalch equation, where pK9 (6.1, 378C) wasand the HCTZ 1 KHCO3 group comprised 18 subjects. A
corrected for pH and body temperature [18], and thethird group of patients treated with 60 mmol/day KHCO3
solubility coefficient of carbon dioxide in plasma (0.0301,alone were studied for comparative purposes (KHCO3
378C) was corrected for body temperature [18]. Bloodgroup, N 5 19 subjects). The subjects remained on their
pH values were also corrected for body temperature [18].self-selected diets throughout the study and were in-
Urine bicarbonate concentration was calculated from thestructed not to change their customary dietary habits dur-
measured values of urine pH and carbon dioxide contenting the study. Baseline periods were 7 to 14 days, and
using the Henderson-Hasselbalch equation, where thethe treatment periods were 14 days. In the two groups
solubility coefficient of CO2 is taken as 0.0309 and pK9receiving HCTZ, subjects returned to clinic for blood
is corrected for ionic strengthcollections and to submit 24-hour collections on three
days during each of the two periods, with treatment pK9 5 6.33 2 0.5([Na1] 1 [K1])1/2
period collections performed between days 7 and 14 of
where Na1 and K1 concentrations are expressed in Eq/L.treatment. The KHCO3 only group returned for collec-
Net acid excretion (NAE) was calculated as the sum oftions only twice during baseline and treatment periods.
the excretion rates of titratable acid and ammonium minusAlthough administration of KHCO3 alone is known
that of bicarbonate. Titratable acid concentration was de-to reduce urine calcium excretion, for comparative pur-
poses, we needed to know the magnitude of its effect termined by titration, and urine ammonium concentration
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Table 2. Change from baselineTable 1. Baseline values
HCTZ 1 HCTZ 1 DHCTZ 1 DHCTZ1
KCl KHCO3 DKHCO3Item KCl KHCO3 KHCO3
(N 5 13) (N 5 18) (N 5 19)
Age years 6366 61 615 6267
Sex M:F 5:8 5:13 0:19 Blood
pH 0.0360.02a 0.0460.02a ndWeight kg 68616 72617 6568
Height cm 167612 169611 16167 HCO3 mEq/L 1.261.4a 3.261.2a,b nd
K mEq/L 20.160.4c,d 20.460.2a,b,d 0.160.3b,cBody mass index kg/m2 24.262.9 25.163.7 25.263.2
Blood pH 7.4060.01 7.4160.02 — Urine
K mEq/d 58621 46617 48623Blood PCO2 mm Hg 4062 40 63 —
Plasma HCO3 mEq/L 2461 2562 — Na mEq/d 13631 21636 210641
Ca mmol/d 20.8061.00a 21.8261.15a,b,d 20.7060.60aSerum K mmol/L 4.360.2 4.360.3 4.360.2
UNaV mEq/d 121652 127646 110630 NAE mEq/d 5619c,d 252612b,d 238619b,c
UClV mEq/d 118640 119645 107628 HCTZ, thiazide; KHCO3, potassium bicarbonate; KCl, potassium chloride;
UKV mEq/d 75619 63624 70632 nd, not done
UNAEV mEq/d 42620 43618 28614 a P , 0.05 compared with baseline
UCaV mmol/d 4.062.2 3.662.5 3.661.4 b Different from HCTZ 1 KCl, P , 0.05
c Different from HCTZ 1 KHCO3, P , 0.05UPO4V mmol/d 9.163.0 8.563.0 8.662.3
d Different from KHCO3, P , 0.05.ClCr mL/min/1.73 m2 86621 83613 76615
was determined as previously described [5]. Net endoge-
nous acid production was estimated from NAE.
Data points for each subject were the average of those
obtained from the three initial and the two or three final
blood and urine samples. For each variable for each
subject, we computed the magnitude of change from
baseline (that is, delta values) and then performed one-
way analysis of variance (ANOVA) on those delta values
to determine whether the mean delta values among the
three treatment groups differed significantly. When the
three treatment means were found to differ, we per-
formed, post hoc, the Student–Newman–Keuls test for
paired comparisons between groups to determine which
means were significantly different from each other. The
Fig. 1. Change in urine calcium excretion (DUCaV) in the three treat-paired t-test was used to assess significant changes pro- ment groups.
duced within groups. Data are reported as mean 6 SD.
All statistical analyses were done using Sigmastat (Jandel
Inc., San Rafael, CA, USA).
Urinary calcium excretion decreased significantly inAll studies were approved by the University of Califor-
all groups (Table 2 and Fig. 1). With KHCO3 alone andnia San Francisco Institutional Review Board.
HCTZ 1 KCl, UCaV decreased to approximately the
same extent (20.70 6 0.60 vs. 20.80 6 1.00 mmol/day,
RESULTS P , 0.001 and P , 0.002, respectively). The combination
of HCTZ 1 KHCO3 was superior to either group in reduc-At baseline, there was no significant difference in the
24-hour urinary excretion rates of sodium, potassium, or ing UCaV (21.82 6 1.24 mmol/day), inducing more than
a twofold greater reduction in urine calcium excretion thancalcium among groups (Table 1). UCaV was normal in
all groups (average 3.7 6 2.0 mmol/day). Subject compli- did either HCTZ 1 KCl or KHCO3 alone (P , 0.05).
There was a clear direct relationship between the de-ance was measured by weekly pill counts and urinary
potassium excretion. The increase in potassium excretion cline in urine calcium excretion and the absolute value
of the baseline urine calcium excretion (P , 0.01) inwas consistent with the taking of 60 mEq of potassium
per day, indicating that the subjects were highly compli- both groups treated with HCTZ, but not in the group
treated with KHCO3 alone. For the HCTZ 1 KHCO3ant with the regimen (Table 2); there was no significant
difference among groups. group, the regression analysis was DUCaV 5 220.6 2
0.325 · UCaV; for the HCTZ 1 KCl group, the regressionRenal function, as measured by repeated 24-hour
urine creatinine clearances (mL/min/1.73 m2), was not analysis was DUCaV 5 113.7 2 0.322 · UCaV. For each
treatment group and for all three treatments groups com-significantly different among groups before treatment
(Table 1) or within groups in response to treatment. bined, the magnitude of the change in urine Ca did not
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correlate with the dose of potassium administered per kg sium chloride would have mitigated the hypocalciuric
effect of HCTZ. HCTZ alone can decrease urine calciumbody weight or per gram of creatinine excreted. Finally,
for each HCTZ treatment group, the magnitude of the excretion, but often causes hypokalemia, particularly in
the doses used in the present study. Potassium deficiencychange in urine Ca did not correlate with the dose of
HCTZ administered (per gram of creatinine excreted). has been shown to promote urinary calcium loss, which
is reversed by potassium supplementation [abstract;Data were also analyzed to determine whether the
combination of HCTZ 1 KHCO3 or KHCO3 alone was Lemann et al, J Bone Miner Res 5(Suppl 2):S203, 1990]
[17]. Testing HCTZ alone therefore was not consideredsuperior to that of HCTZ 1 KCl in neutralizing the
net acid load of the diet (Table 2). HCTZ 1 KCl had to be a necessary arm of our study.
Might the combination of HCTZ plus KHCO3 workessentially no effect on NAE. Both HCTZ 1 KHCO3
and KHCO3 reduced NAE significantly and to slightly even better in subjects with hypercalciuria than in normal
subjects? In subjects with hypercalciuria and renal stones,negative values: for HCTZ 1 KHCO3, 210 mEq/day
(baseline, 42 mEq/day; change with treatment, 252 mEq/ HCTZ or potassium citrate are commonly used treatments
but are given for different reasons: HCTZ to facilitateday); for KHCO3, 210 mEq/day (baseline, 28 mEq/day;
change with treatment, 238 mEq/day). renal reclamation of calcium and potassium citrate as an
alkalinizing agent to correct hypocitraturia, which is anBlood pH rose from baseline in both thiazide groups
(P , 0.001), as did the plasma bicarbonate concentration independent risk factor for stone formation. Thus, sub-
jects who are both hypercalciuric and hypocitraturic are(HCTZ 1 KCl, P , 0.01; HCTZ 1 KHCO3, P , 0.001;
Table 2). Serum potassium concentration decreased in placed on both medications. Our data suggest that it may
be reasonable to place subjects who are hypercalciuricthe thiazide groups, although all serum potassium levels
remained within the limits of normal (3.5 to 4.5 mEq/L). on both HCTZ and an alkalinizing salt of potassium
whether or not they have hypocitraturia.There were no significant changes in body weights
with any treatment. Although sodium chloride intake was not controlled
in our subjects and increased sodium chloride intake is
known to increase the rate of calcium excretion in the
DISCUSSION
urine, in our subjects, mean sodium and chloride excre-
Urinary calcium excretion decreased significantly in tion, and therefore presumably also consumption, did
response to the administration of HCTZ in combination not differ significantly among groups, and hence cannot
with either KHCO3 or KCl and in response to the admin- account for the observed differences in UCaV. Creatinine
istration of KHCO3 alone. Previous studies have shown clearance also did not differ among groups. Subjects
that in normal, healthy people, thiazides decrease urine were excluded from the study if they were taking any
calcium excretion [19] and that potassium alkali salts also medication or had any medical conditions that affected
decrease urine calcium excretion [5, 20]. Urine calcium bone or calcium metabolism.
excretion therefore decreased as expected in the KHCO3 Blood pH and plasma bicarbonate concentration in-
group and in both HCTZ groups. With respect to reduc- creased slightly but significantly in the HCTZ 1 KHCO3
ing urine calcium, HCTZ 1 KHCO3 should have been group, but not in the HCTZ 1 KCl group (Table 2).
at least as effective as KHCO3 treatment alone. In fact, However, the values remained within the range consid-
the effects of the two treatments were additive so that ered to be normal. By reducing NAE to near zero values,
treatment with HCTZ and KHCO3 combined doubled the effect of HCTZ 1 KHCO3 may be viewed as resetting
the decrement in urinary calcium observed with either blood pH and plasma bicarbonate to a nonacidotic level
KHCO3 treatment alone or that observed during com- rather than to an alkalotic level.
bined treatment with HCTZ and KCl. It may be asked of what physiologic significance is a
In this study, neither HCTZ nor KCl alone was tested. decrease in urine calcium excretion of the magnitude
It might be argued that the chloride component of KCl, observed with HCTZ 1 KHCO3, namely 1.8 mmol/day
by promoting urine calcium excretion, mitigated the hy- (73 mg/day). Perimenopausal women on an average cal-
pocalciuric effect of HCTZ and thereby accounted for cium diet of 16.5 mmol/day (661 mg/day) have an average
some of the differential effect of HCTZ 1 KHCO3 versus negative calcium balance of between 0.60 and 0.78 mmol/
HCTZ 1 KCl on urine calcium excretion. However, chlo- day (24 to 31 mg/day) [21]. Men and women with un-
ride is not calciuric when administered as potassium chlo- treated osteoporosis on a 30 mmol/day (1200 mg/day)
ride [16, 17]. The contrasting effect of various potassium calcium diet have been shown to have an average nega-
salts on UCaV was specifically studied by Sakhaee et al tive calcium balance of 0.25 mmol/day (10 mg/day) [22].
[16] and Lemann [17], both of whom found that com- A decrease in the amount of urinary calcium loss of 1.8
pared with control, potassium chloride had no effect on mmol/day (73 mg/day) in the HCTZ 1 KHCO3 group
UCaV, whereas potassium bicarbonate (or citrate) signifi- might then induce a positive calcium balance in patients
with osteoporosis. In a preliminary report of patients withcantly reduced it. Therefore, it seems unlikely that potas-
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